Please assess the completion status of the following clinical trial:

Trial Title: A Safety Study of SGN-CD48A in Patients With Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of MM requiring systemic therapy (per the International Myeloma Working Group \[IMWG\])~* Patients must not have other therapeutic options known to provide clinical benefit in MM available to them. Prior lines of therapy must include at least a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.~* Measureable disease, as defined by at least one of the following: serum M protein 0.5 g/dL or higher, urine M protein 200 mg/24 hour or higher, and serum immunoglobulin free light chain 10 mg/dL or higher and abnormal serum immunoglobulin kappa lambda free light chain ratio~* Adequate hematologic, renal, and hepatic function~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* Life expectancy greater than 3 months~* A negative pregnancy test (for females of childbearing potential)~* Patients must provide written consent~Exclusion Criteria:~* Pre-existing peripheral neuropathy Grade 2 or higher~* History of malignancy other than MM within the past 3 years~* Active cerebral/meningeal disease related to the underlying malignancy~* Uncontrolled Grade 3 or higher infection~* Known to be positive for HIV or hepatitis B, or known to have active hepatitis C infection~* Previous allogeneic stem cell transplant~* History of cerebral vascular event, unstable angina, myocardial infarction, or cardiac symptoms consistent with congestive heart failure within the last 6 months~* Treatment with any known P-gp inducers/inhibitors or strong CYP3A inhibitors within 14 days prior to the first dose of study drug~* Prior antitumor therapy that is not completed at least 4 weeks prior to first dose of study drug, or at least 2 weeks if progressing. Prior CAR T-cell therapy must be completed 8 weeks before first dose of study drug.~* Females who are pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SGN-CD48A (Type: EXPERIMENTAL): SGN-CD48A

Based on this trial design, predict the completion outcome and termination type (if applicable).